RE-BVS – Piemonte Repository

Sfoglia per AUTORE
VAN DER VELDEN VHJ
Collezione AOU Città della Salute di Torino

Items : 4

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AOU Città della Salute di Torino

Benjamin R; Hájek R; Zweegman S; Silkjaer T; Caers J; Mancuso K; Tacchetti P; Razawy W; Grasso M; Giaccone L; Offidani M; Lund T; van der Velden VHJ; Pour L; Gadisseur A; Pietrantuono G; Broijl A; Roeloffzen WWH; Wu KL; Schjesvold F; van der Holt B; Minnema MC; van de Donk NWCJ; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P;

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3132-3150. doi: 10.1200/JCO.21.01217. Epub 2022 Mar 31.

2022
AOU Città della Salute di Torino

Moreau P; Musto P; Munshi NC; Avet-Loiseau H; Gay F; Broijl A; Vermeulen M; Valent ET; Beverloo HB; van der Holt B; Hoogenboezem R; van der Velden VHJ; Cupedo T; van Duin M; Kuiper R; Hofste Op Bruinink D; Zweegman S; van de Donk NWCJ; Sonneveld P;

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. in Blood cancer journal / Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0.

2021
AOU Città della Salute di Torino

Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...